Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Thwarting thrombogenesis on artificial surfaces
0
Zitationen
1
Autoren
1982
Jahr
Abstract
The usefulness of heart-lung machines, synthetic vascular grafts, and other cardiovascular replacement or support devices is undisputed, but they share a common disadvantage: Thrombi may form on the artificial surfaces, interfering with the device itself or eventually lodging in one of the patient's organs. The problems begin, says Edwin W. Salzman, MD, professor of surgery at Harvard Medical School and Beth Israel Hospital, Boston, when "certain proteins carried in the plasma—fibrinogen is one of the most important—are selectively deposited on a surface in a thin coat. "It is this thin film of protein," he told a recent American Heart Association seminar, "not the surface of the artificial material, that influences other blood proteins and platelets to find the surface attractive or unattractive and thus thrombogenic or thromboresistant." There are two possible ways to cope with this, and Salzman's group is studying both. One is to develop artificial surfaces that are
Ähnliche Arbeiten
A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care
1999 · 5.203 Zit.
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial
2010 · 3.238 Zit.
Transfusion of Plasma, Platelets, and Red Blood Cells in a 1:1:1 vs a 1:1:2 Ratio and Mortality in Patients With Severe Trauma
2015 · 2.437 Zit.
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
2020 · 2.420 Zit.
A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care
1999 · 2.045 Zit.